The lead author said the results indicate that biologics can be used in older patients with rheumatoid arthritis (RA) as effectively as in those who are younger.
Patients whose rheumatoid arthritis (RA) set in both later in life and earlier in life had similar improvements in disease activity at 48 weeks of treatment with a biologic, according to a study presented at the American College of Rheumatology Annual Meeting in Atlanta, Georgia.
The study assessed the relationship between the age of RA onset and the clinical effectiveness of therapy at 48 weeks. The primary outcome was the Clinical Disease Activity Index (CDAI) score at 48 weeks; secondary outcomes included biologic retention, or drug maintenance rate, at 48 weeks; achievement of a CDAI remission and low disease activity; or remission.
Researchers conducted the study with 7183 patients with RA who were 18 years or older and enrolled in a Japanese multicenter observational registry between September 2009 and December 2017. The inclusion criteria required that patients had to have a 3.2 or higher on the Disease Activity Score in 28 joints (DAS28) and erythrocyte sedimentation rate measurement when they started biologics.
The proportion of patients on biologics was lower in the group for whom RA began at an older age, defined as 60 years and older (18.3% vs 28.0%; P <.001). Of the 989 patients who began biologics, 364 (37%) were defined as elderly.
After adjusting for differences in baseline characteristics between the 2 age groups, there was no significant difference in CDAI score at 48 weeks.
They did find a trend toward lower index remission rates in the over-60 group, but low disease activity/remission rates were similar between both groups (odds ratio, 0.86; 95% CI, 0.29-2.52; P = .77).
Drug maintenance rates (hazard ratio [HR], 0.95; 95% CI, 0.55-1.35; P =.78) and adverse event discontinuation rates (HR, 0.78; 95% CI, 0.38-1.18; P = .22) were similar between the 2 age groups after adjusting for other confounders.
“Patients with elderly-onset RA could present with higher disease activities and increased disabilities as compared to those with young-onset RA. Despite this, previous studies showed elderly patients receive biologics less frequently than younger individuals, suggesting patients with elderly-onset RA are potently undertreated,” said Sadao Jinno, MD, MSc, instructor of rheumatology at Kobe University School of Medicine and the study’s lead author, in a statement. “On the other hand, in our daily practice, we have seen many elderly-onset RA patients treated with biologics effectively and safely. We wanted to investigate if there are differences in efficacy and safety of biologics between the two age groups.”
He said the results suggest that biologics can be used in older-age patients as effectively as in those who are younger.
“Clinicians should choose wisely which patients with elderly-onset RA are safely treated with biologics given that they are still at risk of developing adverse events, especially infections,” he added. “Next, we plan to investigate if patients with elderly-onset RA respond differently to various modes of biologics.”
Reference
Jinno S, Onishi A, Akash K, et al. Are there differences in efficacy and safety of biological disease-modifying antirheumatic drugs between elderly-onset and young-onset rheumatoid arthritis? Presented at: The American College of Rheumatology Annual Meeting, November 8-13, 2019; Atlanta, GA. Abstract 1345.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.